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February 2016 Abstracts S43immunotherapy in this preclinical GEMM model. We ul-
timately plan to test direct MYXV intralesional injection by
navigational bronchoscopy combined with immuno-
therapy to enhance immune mediated targeting of SCLC.
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Wepreviously demonstrated that proximity ligation assays
(PLA) can be utilized to detect EGFR in complex with its
major signaling adaptor GRB2, which couples the receptor
to the MAP kinase pathway to drive oncogenic prolifera-
tion. These “signaling-associated complexes” correlatewith
EGFR activity, reveal erlotinib pharmacodynamics and are
predictive of improved outcomes to EGFR-directed thera-
pies (Smith et al Science Signaling 2015). Here, we use PLA
to assess cMET signaling, which is being actively investi-
gated in late stage clinical trials in lung cancer and other
solid tumors. We found that the presence of cMET:GRB2
complexes correlates with sensitivity to cMET tyrosine ki-
nase inhibitors (TKI) and the interaction is speciﬁcally
abrogated by MET TKI as measured by biochemical ap-
proaches, cellular viability and PLA. In MET-ampliﬁed
patient-derived xenograft models of lung cancer (N¼6) we
observe MET:GRB2 complexes in regions that also stain
strongly using pMET(Y1234/5) immunohistochemistry
(IHC). Treatment of these models with single agent crizo-
tinib led to variable responses as measured by RECIST
criteria. Ongoing experiments are correlating patterns of
PLA positivity with magnitude of response to MET inhibi-
tion. In clinical cohorts of unselected non-small cell lung
cancer patients (N¼409), MET:GRB2 signaling complexes
are rare (observed in <1%), even among patients whose
tumors are highly positive for cMET protein expression as
detected by IHC. In patients with MET gene ampliﬁcation
veriﬁed by FISH, presence of MET:GRB2 complexes were
observed in 6 of 8 patients with variable intensity and
signiﬁcant spatial heterogeneity. The low rates of
MET:GRB2 signaling complexes observed in patient tissues
may potentially explain the poor response rates observed
in clinical trials targeting cMET in lung cancer. Assays that
candetect therapeutically-relevant protein complexeshave
the potential to improve patient stratiﬁcation strategies
and enable precision medicine in oncology.Natural antisense transcript
deregulation in non-small cell
lung cancerGreg L. Stewart, Katey SS. Enﬁeld,
David A. Rowbotham, Roland Hubaux,
Stephen Lam, Wan Lam BC Cancer Research Centre,
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Background: Lung cancer represents an enormous health
burden, representing the most common cause of cancer
death worldwide. The poor therapeutic outcome is largely
due to a complex molecular background as well as late
stage diagnosis, with most patients presenting unresect-
able local tumors, ormetastatic disease.Whilemutations of
driver genes is a well-known mechanism, approximately
half of all non-small cell lung cancer (NSCLC) tumorsharbor
no known clinically relevant oncogenic drivers, empha-
sizing the need to explore alternative mechanisms such as
non-coding RNAs (ncRNAs).
ncRNAs are RNA molecules that do not encode for pro-
tein, but have the ability to regulate DNA, proteins, as well
as other RNA species. These genes exhibit tissue speciﬁc
regulation and have emerged as important players in
several tumor types including lung cancer. Natural anti-
sense transcripts (NATS) are ncRNAs that are transcribed
from the opposite strand of protein coding genes. These
NATs overlapwith, and are often involved in the regulation
of, their sense counterparts. NATs can recruit regulatory
complexes to their transcriptional locus, leading to
silencing of overlapping sense partner gene transcription,
andhave recentlybeendescribed in cancer to silence tumor
suppressor genes such as CDKN2A/B. NATs are quite
prevalent as it is estimated that 25-40% of genes display
overlapping transcriptional partners, emphasizing their
potential in gene regulation. However, only a few NATs
have been characterized in cancer. Here we take an unbi-
ased approach to study NAT deregulation as a mechanism
for altered sense partner expression in NSCLC.
Methods: We performed RNA-sequencing on a set of 65
NSCLC tumors including 36 adenocarcinomas and 29
squamous cell carcinomas as well as
matched nonmalignant lung tissues. A sign-rank test was
used to identify NATs and partner genes with signiﬁ-
cantly altered expression between tumor and matched
normal tissues. These ﬁndings were validated in an
external dataset of lung tumors from TCGA. Survival
analysis was performed using a Cox Proportional hazard
model, as well as the log-rank method.
Results:We have identiﬁed a NAT of OIP5, a lung cancer
oncogene required for chromatin segregation, to be
signiﬁcantly underexpressed in NSCLC. In the same tu-
mors we ﬁnd the overlapping partner gene, OIP5 mRNA,
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AS1 may negatively regulate its sense counterpart. In
addition, we ﬁnd that expression of both OIP5 and OIP5-
AS1 are signiﬁcantly associated with 5-year survival.
These ﬁndings suggest that deregulation of OIP5 through
its antisense RNA may represent a novel mechanism
regulating tumor phenotypes in NSCLC.
ART1, an extracellular
ADP-ribosyltransferase, is
over-expressed in non-small cell lung
cancer and facilitates cancer cell
survival by immune-mediated
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Cell surface mono-ADP ribosyltransferases (ARTs)
transfer the ADP-ribose moiety from NADþ to amino
acid residues on target proteins and post-translationally
regulate their function. Most mammalian mono-ARTs,
including ADP-ribosyltransferase 1 (ART1) reside on the
cell surface, however the scope of extracellular mono-
ADP-ribosylation is largely unknown. It has been sug-
gested that epithelial cells in the injured or inﬂamed lung
may overexpress ART1 as a mechanism of cell survival to
protect against cell clearance by inﬂammatory cells. We
hypothesize that ART1 expression is cytoprotective to
lung cancer cells and facilitates metastatic growth.
We found ART1 to be expressed in multiple human
NSCLC cell lines of distinct driver mutation status by RT-
PCR, western blots, and immunoﬂuorescent staining. Using
biobanked human materials, we also found evidence of
ART1 expression in human NSCLC tumors by whole tumor
RT-PCR, immunoﬂuorescence, and immunohistochemistry.
Compared tomatchedadjacent normal lung (n¼40), byRT-
PCR there is over a 2-fold increase (p¼0.01) in median
tumor expression of ART1, suggesting a role in tumori-
genesis or tumor progression. We subsequently stained a
tissue microarray containing 184 cases of predominantly
(74%) stage I NSCLC to determine the prevalence of NSCLC
tumors staining positive for ART1. ART1 staining was
moderate or strong in 83% of adenocarcinomas (n¼145)
and in 45% of squamous cell cancers (n¼39, p<0.001).
We next used murine cell lines derived from inducible
KRASG12D/þ/p53-/- mice and an in vivo model to deter-
mine the effect of ART1 expression onmetastatic outgrowth.
In a tail vein injection model in immunocompetent mice, we
noted a highly signiﬁcant decrease in metastasis in the
ART1-knockdown cell line (sh175) compared to the parentKP1 line. To determine whether the immune protective ef-
fect mediated by ART1 may be T cell dependent, we
implanted ﬂank tumors in immunocompetent (B6) and
lymphocyte-depleted nude mice. Despite slightly faster in
vitro rates of growth, sh175KP1 cells lacking ART1 expres-
sion were largely unable to form tumors when injected into
the ﬂanks of immunocompetent B6 mice. Only 1 of 5
immunocompetent mice injected with sh175KP1 cells
developed a tumor, compared to 5 of 5 mice injected with
KP1 control cells. However, in lymphocyte-depleted nude
mice, there was robust ﬂank tumor growth with both cell
lines. Because the sh175KP1 cells lacking ART1 only had a
disadvantage to growth in mice with lymphocytes, we can
infer that ART1 expression may have a strong immunomo-
dulating effect on that cell population.We also evaluated the
effect of ART1 expression on neutrophil cytotoxicity. At a
neutrophil:tumor cell ratio of 20:1, the knockdown cell line
sh175KP1 lacking ART1 expression is more sensitive to
neutrophil-induced apoptosis in the co-culture assay (87%
vs. 56% Annexin V positive, p¼0.05). Importantly, chemical
inhibition of mono-ADP-ribosylation in the parent KP1 cell
line with two well established inhibitors, novobiocin and
meta-iodobenzylguanidine, facilitated neutrophil-induced
apoptosis, implying that the enzymatic activity of ART1 is
critical to the phenotype.
We provide evidence that ART1 is overexpressed in
NSCLC. ADP-ribosylation may serve as a defense against
immune-mediated cytotoxicity. Cells without ART1 expres-
sion are more sensitive to cytotoxicity induced by immune
cells and these cells have a markedly decreased capacity to
grow in the lungs in an immunocompetentmetastaticmodel.
Because ART1 is an extracellular enzymatic target, it is ex-
pected to be highly druggable and susceptible to therapeutic
intervention. We envision using targeted inhibition of ADP-
ribosylation in ART1-overexpressing tumors to facilitate
immune-mediated destruction of established cancers or of
micrometastatic disease.
Routine molecular testing of resected
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Introduction: Molecular testing is routinely performed in
patients with metastatic non-small cell lung cancer. As the
